Recombinant Human Type 2 Necrotic Tumor Factor for Injection generally refers to Recombinant Human Type II Tumor Necrosis Factor Receptor-Antibody Fusion Protein for Injection, which is a medication for the treatment of active rheumatoid arthritis, plaque psoriasis, and active ankylosing spondylitis. Recombinant Human Type II Tumor Necrosis Factor Receptor-Antibody Fusion Protein for Injection can competitively bind to tumor necrosis factor, inhibit the activity of tumor necrosis factor, and block the signaling of immune cells, thus regulating the process of inflammatory response. It can treat moderate and severe active rheumatoid arthritis, moderate to severe plaque psoriasis in adults ≥18 years old, and active ankylosing spondylitis. Adverse reactions such as pain and swelling at the injection site, headache, dizziness, and rash can occur after injection. It is contraindicated in people who are allergic to the active ingredient of the product or other ingredients in the formulation; patients with sepsis or at risk of sepsis; and patients with severe active infections, including chronic or localized infections. The drug is a prescription drug, patients need to strictly follow the doctor’s instructions to use the drug.